Old tale new admirers, cetuximab maintenance in metastatic colorectal cancer: a systematic review and meta-analysis
Frontiers in Pharmacology · 03.06.2026 · 17
DOI: 10.3389/fphar.2026.1845800 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Frontiers in Pharmacology, online erschienen am 03.06.2026. Verfasst von Yici Yan und 6 weiteren Autor:innen. Beteiligte Einrichtung: The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, China. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background metastatic colorectal cancer (mCRC) represents a major global burden and the decision on whether to pursue maintenance with cetuximab (CET) remains controversial. Therefore, this meta-analysis was performed to assess the efficacy and safety of CET maintenance therapy.
Methods
After literature search of PubMed, Embase, Cochrane Library and Scopus from inception to March 2026, two investigators selected eligible studies and extracted relevant data. The key outcomes were progression-free survival (PFS) and overall survival (OS). A random-effects model was used for pooling. The relative risks (RRs) with 95% confidence interval (CI) of all-grade and high-grade (≥3) adverse effects (AEs) were used to study its safety. Heterogeneity was also investigated through subgroup and sensitivity analysis.
Results
A total of 6 studies with 727 patients were included. CET maintenance therapy prolonged the PFS (HR: 0.42, 95% CI: 0.27 to 0.57, P < 0.01) and OS (HR: 0.47, 95% CI: 0.19 to 0.74, P < 0.01) of mCRC patients. Subgroup analysis showed that Asian patients (HR: 0.53, 95% CI: 0.15 to 0.60, P = 0.010) received more survival benefit from CET maintenance therapy than non-CET therapy or observation. Although diarrhea and rash were more common, the RR of all-grade AEs revealed no statistical significance.
Conclusion
CET maintenance therapy may be associated with improved outcomes compared with observation, especially in Asian patients. But it may slightly increase treatment-related toxicities. Therefore, subsequent large sample, multi-center randomized controlled trials (RCTs) are needed to further verify our conclusions. Systematic Review Registration https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42024513879 , identifier CRD42024513879.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, China.
- Academy of Chinese Medical Science, Zhejiang Chinese Medical University, Hangzhou, China.
- Key Laboratory of Neuropharmacology and Translational Medicine of Zhejiang Province, School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, China.
- Longyou Hospital of Chinese Medicine, Quzhou, Zhejiang, China.
Zitieren
APA
Yan, Y., Lin, Z., Yuan, J., Gao, W., Jiao, C., Sun, L., & Sun, X. (2026). Old tale new admirers, cetuximab maintenance in metastatic colorectal cancer: a systematic review and meta-analysis. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1845800
Vancouver
Yan Y, Lin Z, Yuan J, Gao W, Jiao C, Sun L, et al. Old tale new admirers, cetuximab maintenance in metastatic colorectal cancer: a systematic review and meta-analysis. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1845800
BibTeX
@article{Yan2026,
author = {Yan, Yici and Lin, Zhenyi and Yuan, Jing and Gao, Weidong and Jiao, Chenxu and Sun, Leitao and Sun, Xun},
title = {Old tale new admirers, cetuximab maintenance in metastatic colorectal cancer: a systematic review and meta-analysis},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1845800}
}
EUVIMED